Cefepime Dosing in Neonates: What is the Evidence?

Area of Science:

• Neonatal pharmacology
• Pediatric infectious diseases
• Antibiotic stewardship

Background:

• Cefepime dosing recommendations for neonates lack standardization across references.
• Variations in recommended dose and frequency necessitate a review of current evidence.
• Accurate cefepime dosing is crucial for effective neonatal infection management.

Purpose of the Study:

• To consolidate and critically assess existing literature on cefepime dosing in neonatal populations.
• To provide evidence-based guidance for cefepime administration in neonates.
• To address discrepancies in cefepime dosing strategies.

Main Methods:

• Comprehensive literature search of MEDLINE using "cefepime" as the keyword.
• Inclusion criteria: English language, human subjects, patients under 2 months of age.
• Evaluation of four pharmacokinetic studies and two clinical practice studies.

Main Results:

• A 12-hour dosing interval for cefepime demonstrated adequate pharmacokinetic parameters in neonates for minimum inhibitory concentrations (MIC) ≤ 8 mg/L.
• Clinical outcome studies reported seizures and hypophosphatemia as the most common adverse effects.
• A regimen of 50 mg/kg per dose every 12 hours achieved microbiologic cure.

Conclusions:

• Cefepime at 30-50 mg/kg per dose every 12 hours may achieve target concentrations (2-4 times MIC) for at least 60% of the dosing interval in neonates with MICs ≤ 8 mg/L.
• This dosing strategy supports effective cefepime therapy in neonatal patients.
• Further research may refine optimal cefepime dosing protocols for neonatal care.